Thema: Studie: Intratumoral carboplatin levels
Studie: Intratumoral carboplatin levels
Anne[a]
14.06.2004 09:47:43
Pilot Study of Intratumoral Carboplatin Levels in Patients with High Grade Gliomas and Brain Metastases
Min Karnofsky Score:
40: Requires special care and assistance; disabled
Conditions:
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Metastatic and Primary Brain Tumors
Tumor Types:
Anaplastic Astrocytoma
Glioblastoma Multiforme
Metastatic Brain Tumor
Comments:
Each year in the United States approximately 17,000 people are diagnosed with primary malignant brain tumors (CBTRUS, 2000). Malignant glial tumors, including anaplastic astrocytoma and GBM, exact a tremendous toll on patients because of the severe neurological disability they produce. Despite optimum treatment modalities of maximal tumor removal, radiation, and adjuvent chemotherapy, the prognosis for these tumors is bleak with survival rates of 12 to 18 months (Neurosurgery, 1991). The dismal survival rate of less than 25% for patients with recurrent (have come back) and progressive (have gotten worse) metastatic brain tumors has prompted us to seek further understanding on how chemotherapy drugs act in the body over a period of time including how they`re absorbed, distributed, localized in tissues, and excreted. Typically, drugs used to treat brain tumors are only minimally successful at crossing the blood-brain barrier (a protective membrane that prevents potentially harmful substances from moving out of the bloodstream into the brain). Impaired delivery of the drugs across the blood-brain barrier has been a major obstacle in the treatment of brain tumors. The purpose of this study is to determine intratumoral (inside the tumor) and serum (blood) levels of a frequently used chemotherapy drug, Carboplatin. We propose treating 10 patients with Ondansetron (an anti-nausea medication) intravenously (through the vein) followed by Carboplatin 100 mg intravenously 30 minutes later approximately 2 to 6 hours prior to planned tumor resection. At the time of the tumor resection, a serum (blood) sample (1-2 tablespoons) will be obtained. Using specific markers, the quantity of serum and intratumoral Carboplatin will be determined. The data we compile will allow us to better understand the drug properties of intratumoral chemotherapy treatment and will be used as comparative values in future blood-brain barrier studies. Once this data is compiled, modification of these treatments may be possible in treating future patients with brain tumors.
Treatment Type: Chemotherapy
Contact:
Keith L. Black MD
Director
Cedars-Sinai Maxine Dunitz Neurosurgical Institute
8631 W. Third Street
Suite 800 E
Los Angeles, CA 90048 USA
Phone: 310-423-7900
Fax: (310) 423-0810
E-mail: csnsi@cshs.org
Min Karnofsky Score:
40: Requires special care and assistance; disabled
Conditions:
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Metastatic and Primary Brain Tumors
Tumor Types:
Anaplastic Astrocytoma
Glioblastoma Multiforme
Metastatic Brain Tumor
Comments:
Each year in the United States approximately 17,000 people are diagnosed with primary malignant brain tumors (CBTRUS, 2000). Malignant glial tumors, including anaplastic astrocytoma and GBM, exact a tremendous toll on patients because of the severe neurological disability they produce. Despite optimum treatment modalities of maximal tumor removal, radiation, and adjuvent chemotherapy, the prognosis for these tumors is bleak with survival rates of 12 to 18 months (Neurosurgery, 1991). The dismal survival rate of less than 25% for patients with recurrent (have come back) and progressive (have gotten worse) metastatic brain tumors has prompted us to seek further understanding on how chemotherapy drugs act in the body over a period of time including how they`re absorbed, distributed, localized in tissues, and excreted. Typically, drugs used to treat brain tumors are only minimally successful at crossing the blood-brain barrier (a protective membrane that prevents potentially harmful substances from moving out of the bloodstream into the brain). Impaired delivery of the drugs across the blood-brain barrier has been a major obstacle in the treatment of brain tumors. The purpose of this study is to determine intratumoral (inside the tumor) and serum (blood) levels of a frequently used chemotherapy drug, Carboplatin. We propose treating 10 patients with Ondansetron (an anti-nausea medication) intravenously (through the vein) followed by Carboplatin 100 mg intravenously 30 minutes later approximately 2 to 6 hours prior to planned tumor resection. At the time of the tumor resection, a serum (blood) sample (1-2 tablespoons) will be obtained. Using specific markers, the quantity of serum and intratumoral Carboplatin will be determined. The data we compile will allow us to better understand the drug properties of intratumoral chemotherapy treatment and will be used as comparative values in future blood-brain barrier studies. Once this data is compiled, modification of these treatments may be possible in treating future patients with brain tumors.
Treatment Type: Chemotherapy
Contact:
Keith L. Black MD
Director
Cedars-Sinai Maxine Dunitz Neurosurgical Institute
8631 W. Third Street
Suite 800 E
Los Angeles, CA 90048 USA
Phone: 310-423-7900
Fax: (310) 423-0810
E-mail: csnsi@cshs.org
Anne[a]
